Alzamend Neuro Inc. Common Stock ALZN · Stock Open Alzamend Neuro Inc. Common Stock in new tab
Alzamend Neuro Inc. Common Stock Analysis (ALZN)
Is Alzamend Neuro Inc. Common Stock a good investment? Alzamend Neuro Inc. Common Stock (ALZN) is currently trading at 1.32 USD.
Earnings Schedule: Alzamend Neuro Inc. Common Stock is expected to release its next earnings report on Dec. 8, 2026. The market consensus estimate for Forward EPS is -0.87.
Investor FAQ
Does Alzamend Neuro Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Alzamend Neuro Inc. Common Stock?
Alzamend Neuro Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Dec. 8, 2026. The company currently has a trailing EPS of -2.03.
Company Profile
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 31, 2023 | 0.07 |
| July 16, 2024 | 1:10 |
| May 12, 2025 | 0.11 |
Community Discussion